Enclomiphene Dosage: Doses Studied, Units and Chart
What doses of Enclomiphene have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 5 studies
- with a stated dose, listed below
- Frequency
- daily
- as used in studies
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| two doses of enclomiphene citrate vs testosterone gel (AndroGel 1.62%) | daily · oral · 16 weeks | Human RCT | BJU international 2016, PMID 26496621 |
| 6.25, 12.5 or 25 mg | daily · oral · six weeks | Human RCTn = 48 | BJU international 2013, PMID 23875626 |
| 50 mg daily (inadvertent; prescribed 25 mg) | oral | Human case reportn = 1 | Cureus 2026, PMID 42741668 |
| enclomiphene citrate 12.5-25 mg daily; clomiphene 12.5-50 mg daily | oral · 1.5-4 months | Meta-analysisn = 292 | Andrology 2023, PMID 36604313 |
| 4 and 40 mg/kg/day enclomiphene | oral gavage | Animal · mouse (not a human result) | BJU international 2016, PMID 26220499 |
Before anyone considers it
- Enclomiphene is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Daily oral amounts in the male hypogonadism trials
A phase II study compared 6.25 mg, 12.5 mg and 25 mg daily oral enclomiphene citrate with transdermal testosterone in men with secondary hypogonadism.[4]
At Day 42 the mean total testosterone was 604 ng/dL on the highest enclomiphene amount (25 mg daily).[4]
Phase III trials (ZA-304 and ZA-305) compared enclomiphene citrate doses with testosterone gel, measuring hormone levels after 16 weeks of treatment in overweight men aged 18-60 years with secondary hypogonadism.[3]
What happened above the studied range
A case report describes a 46-year-old man who took 50 mg daily in place of 25 mg daily and had atrial flutter documented shortly afterwards. The authors say causality cannot be established.[5]
No approved product
Drugs@FDA lists no enclomiphene product, so no label sets an approved amount.[13]
Common questions
Is Enclomiphene FDA approved?
No. Enclomiphene is not FDA approved for any use.
What is the enclomiphene citrate dosage in trials?
The phase II trial used 6.25 mg, 12.5 mg and 25 mg daily orally, against a transdermal testosterone comparator.[4]
Is there an enclomiphene dosage for bodybuilding?
The cited trials enrolled men with secondary hypogonadism, not bodybuilders. Drugs@FDA lists no enclomiphene product.[13]
Is there an enclomiphene cycle?
The phase III trials assessed hormone levels after 16 weeks of treatment; the abstract describes no cycle or planned break.[3]
More on Enclomiphene
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.BJU international · 2016PMID 26496621Accessed 2 Oct 2026
- 4Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.BJU international · 2013PMID 23875626Accessed 2 Oct 2026
- 5Newly Detected Atrial Flutter After Enclomiphene Dose Escalation in a Patient With Prior Mitral Valve Repair and Chronic Immune Thrombocytopenia: A Case Report.Cureus · 2026PMID 42741668Accessed 2 Oct 2026
- 6Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis.Andrology · 2023PMID 36604313Accessed 2 Oct 2026
- 7Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice.BJU international · 2016PMID 26220499Accessed 2 Oct 2026
- 8PubMed search: enclomiphene[tiab] OR enclomifene[tiab] OR "trans-clomiphene"[tiab] (98 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt] OR meta-analysis[pt]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (hypogonadism[tiab] OR testosterone[tiab]) AND humans[mh] (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: enclomiphene[tiab] OR enclomifene[tiab] OR Androxal[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 13Drugs@FDA (openFDA) search: active ingredient "enclomiphene"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.